@FiercePharma: Generics makers need to change their spots--and learn marketing--to sell biosimilars, Actavis CEO says. More | Follow @FiercePharma
> European regulators wrapped up a safety review of GlaxoSmithKline's ($GSK) flu shot Pandemrix, saying evidence linking it with narcolepsy is "insufficient." Report
> Greece dropped plans to claw back pharma industry revenues to make up for overspending on outpatient drug therapy, but apparently cut some branded drugs from its new formulary. Report
> U.S. officials confirmed that a deadly fungus implicated in a meningitis outbreak was present in one lot of steroids supplied by New England Compounding Center. Report
> The FDA plans to allow Sun Pharmaceuticals to continue importing its version of the Johnson & Johnson ($JNJ) cancer drug Doxil until the branded product shortage completely resolves. Report
> AstraZeneca ($AZN) won a £5 million investment from a U.K. government fund to back its efforts toward a potential BioScience cluster at its R&D facility in Alderley Park. Report
@FierceMedDev: VC investment in Q3 is way down for medical devices. More | Follow @FierceMedDev
@MarkHFierce: So what were the top med device VC deals in the 2012 third quarter? More | Follow @MarkHFierce
@DamianFierce: Steris is spending $110M on M&A to expand its surgical device capabilities. More | Follow @DamianFierce
> Complete Genomics scores patent win over Illumina. Story
> Study: To reduce heart disease risks, gastric banding beats drugs. News
> Sony slashes jobs on road to medical device focus. Item
Biotech News
@FierceBiotech: Wanted: Premier hepatitis C drug developer to partner with Vertex. More | Follow @FierceBiotech
@JohnCFierce: $1.2B in VC for biotech in Q3 not the best ever, but a whole lot more than we've been seeing--so I see it as a solid +. More | Follow @JohnCFierce
> Novo's long-acting insulin degludec takes big step to megamarket status. Story
> Wanted: Premier hepatitis C drug developer to partner with Vertex. News
> U.K.'s Redx blueprints big R&D spinoff funded by government grant. Article
And Finally... Blood hormone tests predicted a woman's risk for developing postmenopausal breast cancer for up to 20 years, a new study found. Report